STOCK TITAN

Novavax, Inc. - NVAX STOCK NEWS

Welcome to our dedicated news page for Novavax (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Novavax's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Novavax's position in the market.

Rhea-AI Summary
Novavax, Inc. (Nasdaq: NVAX) to Participate in Jefferies London Healthcare Conference, Fireside Chat with CEO and President, Investor Meetings, and Recorded Session Available
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
conferences
-
Rhea-AI Summary
Novavax, Inc. (NVAX) Receives FDA and European Commission Approval for Updated COVID-19 Vaccine, Announces Financial Results and Operational Highlights for Q3 2023. Key points include the launch of a non-mRNA vaccine, WHO recommendation for the Matrix-M malaria vaccine, and anticipated Phase 3 COVID-19-Influenza Combination vaccine trial. The company also plans to initiate a cost reduction program to align with future market opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Novavax, Inc. will report its Q3 2023 financial results and operational highlights on November 9, 2023, at 8:30 a.m. EST. Conference call details and replay information are provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences earnings
Rhea-AI Summary
Novavax's updated COVID-19 vaccine, Nuvaxovid™ XBB.1.5 dispersion for injection, has been granted approval by the European Commission for individuals aged 12 and older. The vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union. Novavax is working closely with EU member states to deliver the vaccine to those that have requested doses through the advance purchase agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
covid-19
-
Rhea-AI Summary
Novavax's Nuvaxovid™ XBB.1.5 COVID-19 vaccine has been recommended for approval in the European Union for individuals aged 12 and older. The vaccine has shown immune responses against multiple variants and is expected to receive final approval soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
covid-19
-
Rhea-AI Summary
Novavax receives full marketing authorization for its prototype COVID-19 vaccine in the UK
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
covid-19
Rhea-AI Summary
Novavax's prototype COVID-19 vaccine receives full approval in Singapore for individuals aged 12 and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
covid-19
-
Rhea-AI Summary
Novavax announces agreements with major pharmacy retailers to provide its COVID-19 vaccine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
covid-19
-
Rhea-AI Summary
Novavax to present study findings on COVID-19 vaccines at IDWeek and World Vaccine Congress Europe
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
none
Rhea-AI Summary
Novavax partners with HealthyWomen and Nicole Ari Parker to launch Choose to Protect campaign to educate the public about COVID vaccination and vaccine options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
covid-19
Novavax, Inc.

Nasdaq:NVAX

NVAX Rankings

NVAX Stock Data

599.00M
125.20M
4.99%
56.33%
31.37%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Gaithersburg

About NVAX

novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"​), seasonal influenza, pandemic influenza, and ebola virus ("ebov"​). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.